A vial labeled BPC-157, Tirzepatide, or Semax is not verified because the label says so. Peptide identity testing methods are the analytical tools used to determine whether the material is actually the claimed compound, rather than a different peptide, a degraded product, or an unidentified mixture.
For research-use-only buyers, identity is the first quality question. Purity percentage, sterile filtration claims, and a discount code may all be relevant later, but none can compensate for a product whose chemical identity has not been established. A meaningful evaluation starts with the right test, performed by an independent laboratory, tied to the actual lot being sold.
What peptide identity testing is meant to prove
Identity testing answers a narrow but essential question: does the submitted sample match the expected molecular structure or molecular mass of the named peptide? That is different from purity testing, which estimates how much of the sample is the main component relative to detectable impurities. It is also different from net content testing, which measures how much peptide is present, and from microbiological testing such as sterility or endotoxin analysis.
A COA that reports “99% purity” without clearly identifying the analyte leaves a major gap. A sample can be highly pure and still be the wrong compound. It can also contain the intended peptide at high chromatographic purity while having less net peptide than the label claim because of moisture, residual solvents, salts, or excipients.
The most useful documentation connects a product name, lot number, test date, laboratory identity, sample description, method, and result. If those details do not align, the report may be real but not necessarily relevant to the vial under review.
The core peptide identity testing methods
LC-MS and high-resolution mass spectrometry
Liquid chromatography-mass spectrometry, usually shortened to LC-MS, is one of the most practical methods for peptide identity confirmation. The chromatography portion separates components in a sample. The mass spectrometer then measures ions associated with the peptide and produces an observed molecular mass that can be compared with the expected theoretical mass.
For many research peptides, an intact-mass result is the clearest first-line identity signal. A high-resolution mass spectrometry result, often called HRMS, provides greater confidence because it can distinguish compounds with very similar masses more precisely. Reports may show a calculated mass, an observed mass, charge states, and a mass error expressed in parts per million.
LC-MS has limits. An intact mass that matches the target does not automatically prove every amino acid is in the correct order, distinguish all structural isomers, or rule out a co-eluting impurity with a similar mass. It is strong evidence when paired with proper chromatographic separation and transparent reporting, but it should not be treated as a universal substitute for deeper structural characterization.
Peptide mapping with LC-MS/MS
Peptide mapping goes further than intact-mass confirmation. The analyte is enzymatically digested into predictable fragments, then those fragments are separated and examined by mass spectrometry. Tandem mass spectrometry, written LC-MS/MS, can provide fragment-level information that supports the peptide sequence.
This method is particularly valuable when a product is high value, structurally complex, modified, or vulnerable to confusion with a closely related analog. It can help distinguish a correctly sequenced peptide from one with a substitution, truncation, deletion, or certain sequence-related errors.
The trade-off is complexity. Peptide mapping requires a validated workflow, appropriate digestion conditions, careful interpretation, and more detailed reporting. A vendor does not need to publish every raw spectrum, but a credible report should identify the method and state what was matched. A vague line reading “identity confirmed” is weaker than documentation that specifies LC-MS/MS peptide mapping or sequence confirmation.
HPLC and UHPLC
High-performance liquid chromatography, or HPLC, is common on peptide COAs. Ultra-high-performance liquid chromatography, UHPLC, is a related technique with higher separation efficiency in many applications. These methods are excellent for estimating chromatographic purity and detecting some impurity peaks.
HPLC alone is not usually sufficient for definitive identity confirmation. Retention time can be compared with a reference standard, but retention time depends on the column, solvent system, gradient, temperature, and instrument conditions. Two different compounds can sometimes produce similar retention behavior under a given method.
A strong COA may pair HPLC purity with LC-MS identity testing. That combination answers two distinct questions: whether the expected mass is present and whether the main chromatographic peak dominates the tested sample. Buyers should be cautious when a supplier presents an HPLC chromatogram as if it proves molecular identity by itself.
Amino acid analysis and related composition tests
Amino acid analysis measures the amino acid composition after the peptide is broken down. It can support whether the expected building blocks are present and can contribute to content assignment in certain workflows. However, it does not independently establish amino acid order. A peptide with the same composition but a different sequence may produce a similar amino acid profile.
This makes amino acid analysis supportive rather than definitive for most sequence-specific identity claims. It is more meaningful when used alongside mass spectrometry and other orthogonal techniques.
NMR spectroscopy
Nuclear magnetic resonance spectroscopy, or NMR, can provide detailed structural information. For smaller molecules, it is often a leading identity technique. For peptides, NMR can be useful but is frequently less practical as a routine release test because spectra may be complex, sample amounts can be substantial, and interpretation requires specialized expertise.
NMR is best viewed as a high-information complementary method. Its presence may strengthen a documentation package for certain compounds, but its absence does not make a peptide COA inadequate when appropriate LC-MS and chromatography data are available.
Why one test is rarely the whole answer
The strongest quality programs use orthogonal testing, meaning methods that examine different properties of the sample. Intact mass supports molecular-weight identity. Peptide mapping can support sequence-level identity. HPLC assesses chromatographic purity. Quantitative assays assess net peptide content. Sterility, endotoxin, and heavy-metal testing examine separate risks that identity methods cannot address.
This distinction matters when comparing vendors. A clean LC-MS result does not establish that the vial contains the labeled milligram amount. A high-purity HPLC result does not establish sterility. A sterility report does not establish peptide sequence. Each claim needs evidence matched to that claim.
At RUO Codes, independent-lab confirmation of identity, purity, and net content is the baseline for supplier inclusion because a single marketing statement cannot replace lot-specific analytical evidence. Higher testing tiers add useful assurance, but they do not erase missing foundational documentation.
How to read identity evidence on a peptide COA
Start by matching the lot number on the COA to the product lot being offered. A generic certificate, a report with no lot number, or a document issued years before the current inventory may not represent the sample in front of you. The test date should also be reasonably current for the lot and product lifecycle.
Next, identify the laboratory. An independent third-party laboratory provides more meaningful evidence than an internally generated report, especially when the lab name, contact details, report identifier, and analyst or reviewer information are available. Independence does not guarantee perfect testing, but it reduces the conflict created when the seller is the only source verifying its own claims.
Then look at the method. For identity, terms such as LC-MS, HRMS, MALDI-TOF MS, LC-MS/MS, intact mass, or peptide mapping are more informative than an unexplained “passed” result. The expected and observed mass should be compatible, with appropriate consideration for common salt forms, charge states, and adducts.
Finally, separate the identity result from purity and quantity results. For lyophilized peptides, the reported material may include acetate, trifluoroacetate, water, or other counterions associated with synthesis and handling. That can affect net-content calculations. A seller should not use a favorable purity number to obscure an unverified quantity claim.
Red flags that weaken an identity claim
Documentation deserves closer scrutiny when it shows a cropped chromatogram with no method details, an unlabeled mass spectrum, a COA that cannot be tied to a lot, or identical reports reused across supposedly different batches. Another concern is a report that lists only HPLC purity while making a broad identity claim.
Be equally careful with terminology. “Tested,” “lab verified,” and “pharmaceutical grade” do not identify the method, laboratory, sample, or result. Research-use-only products should be evaluated on evidence, not regulated-product language that a vendor may not be able to substantiate.
A supplier may have legitimate reasons not to release complete raw data publicly, including laboratory confidentiality and intellectual property considerations. Even so, the public documentation should be specific enough to establish what was tested and what passed. If the evidence cannot be reviewed, it cannot carry much weight in a purchasing decision.
A practical standard for comparing suppliers
For routine comparison, prioritize suppliers that provide current, independent, lot-specific identity testing by mass spectrometry and pair it with chromatographic purity and net-content results. Give additional weight to products supported by sequence-oriented confirmation where the compound, price point, or research context warrants it. Treat sterility, endotoxin, heavy metals, and conformity testing as separate quality layers, not substitutes for identity confirmation.
The useful question is not whether a vendor has a COA. It is whether the COA documents the right product, from the right lot, using a method capable of supporting the claim. When a supplier cannot show that chain of evidence, the responsible move is to keep looking - regardless of the stated purity or the size of the discount.